Background {#Sec1}
==========

Bladder cancer (BC) is one of the most common malignancies over the world, and its incidence and mortality have captured great attention in the past decades \[[@CR1], [@CR2]\]. Although a variety of treatments are available for patients with bladder cancer, such as surgery, chemotherapy and radiation therapy, but the 5-year cancer-specific survival rate remains frustrated \[[@CR3]--[@CR5]\]. Lack of sophisticated understanding of pathogenetic mechanism is one of the most crucial reasons for high case fatality rate of bladder cancer. So, revealing the pathogenetic mechanism of bladder cancer is indispensable for developing an effective diagnosis or treatment.

With the rapid development of second-generation sequencing technology, a multitude of long noncoding RNAs (lncRNAs) have been found to be dysregulated and involved in the development of various human diseases, particularly in cancers \[[@CR6]--[@CR8]\]. Accumulating evidences demonstrated that lncRNAs play important regulatory roles in diverse cellular processes, such as regulation of gene expression, posttranslational processing and tumorigenesis \[[@CR7], [@CR9]\]. BRAF activated non-coding RNA (BANCR), a 693-nt lncRNA encoded on human chromosome 9, has been found to be aberrant expressed in quite a few cancers, such as colorectal cancer \[[@CR10]\], retinoblastoma \[[@CR11]\], melanoma \[[@CR12]\], papillary thyroid carcinoma \[[@CR13]\], lung carcinoma \[[@CR14]\],gastric cancer \[[@CR15]\] and hepatocellular carcinoma \[[@CR16]\]. However, the significance of lncRNA BANCR in bladder cancer is completely unknown.

Thus, in the present research, we identified the clinical significance of lncRNA BANCR in 54 clinical bladder cancer samples and investigated the effects of BANCR expression on bladder cancer cells in vitro. Moreover, further experiments indicated that the overexpression of lncRNA BANCR could inhibit proliferation, induce apoptosis and suppress migration of the bladder cancer cell lines.

Methods {#Sec2}
=======

Patient samples {#Sec3}
---------------

In this research, a total of 54 patients with urothelial neoplasms of the bladder who received radical cystectomy were included. Bladder cancer tissues and their pair-matched adjacent normal tissues were snap-frozen in liquid nitrogen quickly after resection.

Cell lines and cell culture {#Sec4}
---------------------------

Human bladder cancer cell lines (T24, SW780) and SV-40-immortalized human uroepithelial cell line (SV-HUC-1) were purchased from the Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The T24 and SW780 cells were cultured in Dulbecco's Modified Eagle Medium (Invitrogen, Carlsbad, CA, USA) plus 1 % antibiotics (100U/ml penicillin and100 μg/ml streptomycin sulfates) and 10 % fetal bovine serum (FBS). The SV-HUC-1 cells were cultured in F12K (Invitrogen, Carlsbad, CA, USA) plus 1 % antibiotics (100U/ml penicillin and100 μg/ml streptomycin sulfates) and 10 % fetal bovine serum (FBS). All cells were cultured at 37 °C, in a humidified atmosphere with 5 % CO~2~.

Plasmid DNA Transfection {#Sec5}
------------------------

The BANCR sequence and negative control were synthesized and subcloned into pCDNA3.1 (GenePharma, Suzhou, China) vector. The pCDNA-BANCR or negative control was transfected into T24 and SW780 cells cultured in six-well plates using Lipofectamine 3000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The expression level of BANCR was detected by qRT-PCR.

RNA extraction and qRT-PCR {#Sec6}
--------------------------

All total RNA was extracted from bladder cancer tissues or cells after transfection by using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Qualified total RNA was then reverse transcribed to cDNA by utilizing Prime Script RT Reagent Kit with gDNA Eraser (Takara, Dalian, China) following the manufacturer's instructions. The quantitative real-time polymerase chain reaction (qRT-PCR) was executed using SYBR Green PCR kit (Takara, Dalian, China) following the manufacturer's instructions. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was measured as an internal control. The primer sequences were as follows: BANCR primers: 5'- ACAGGACTCCATGGCAAACG-3' (forward) and 5'- ATGAAGAAAGCCTGGTGCAGT-3' (reverse), and GAPDH primers: 5'-CGCTCTCTGCTCCTCCTGTTC-3' (forward), 5'--ATCCGTTGACTCCGACCTTCAC-3' (reverse). The reactions were carried out on an ABI PRISM 7300 Fluorescent Quantitative PCR System (Applied Biosystems, Foster City, CA, USA) in triplicate. The average value in each triplicate was used to calculate the relative amount of BANCR using 2^−ΔΔCt^ methods.

Cell proliferation assays {#Sec7}
-------------------------

Cell proliferation was determined by using Cell Counting Kit-8, CCK-8 (Beyotime Institute of Biotechnology, Shanghai, China) and 5-ethynyl-20-deoxyuridine (Edu) assay kit (Ribobio, Guangzhou, China), respectively, according to the manufacturer's instructions. For CCK-8 assay, 5 × 10^3^cells/ well were seeded in a 96-well plate for 24 h, then transiently transfected with pCDNA-BANCR or negative control. CCK-8 assay was performed according to the previous study. Edu incorporation assay was carried out according to previous studies \[[@CR17]\]. All experiments were performed at least three times.

Caspase-3 ELISA assay {#Sec8}
---------------------

Bladder cancer cells T24 and SW780 were transfected with pCDNA-BANCR or negative control. At 48 h after transfection, the activity of caspase 3 was detected by using the Caspase-3 Colorimetric Assay kit (Abcam, Cambridge, UK) according to the manufacturer's protocol. Each experiment was performed in triplicate.

Flow cytometry assay {#Sec9}
--------------------

T24 and SW780 cells were transfected with pCDNA-BANCR or negative control in normal medium. After 48 h, cells were harvested for flow cytometry assay. After double staining with FITC-Annexin V and PI according to the manufacturer's instructions, cell apoptosis was determined by using flow cytometry (EPICS, XL-4, Beckman, CA, USA).

Transwell assay {#Sec10}
---------------

The cell motility assay were performed using a transwell insert (8 μm, Corning). After 24 h, 5x10^4^ cells transfected with pCDNA-BANCR or negative control were first starved in 200 ml serumfree medium and then placed in the uncoated dishes. Transwell assay was performed according to one previous study \[[@CR18]\].

Statistical analyses {#Sec11}
--------------------

All statistical analyses were executed by using SPSS 20.0 software (IBM, Chicago, IL, USA). Paired samples't test was used to analyze the BANCR expression difference between bladder cancer tissues and para-cancer tissues. CCK-8 assay data were analyzed by ANOVA and independent samples' *t* test was utilized to analyze other data. The chi-square test was used to exam the relationship between BANCR expression level and clinicopathologic characteristics. Differences were considered statistically significant at *p* \< 0.05.

Results {#Sec12}
=======

BANCR was down-regulated in bladder cancer tissues and cells {#Sec13}
------------------------------------------------------------

The relative expression level of BANCR was measured by using qRT-PCR in bladder cancer tissues and pair-matched adjacent normal bladder tissues from 54 bladder cancer patients. Compared with pair-matched adjacent normal bladder tissues, the BANCR expression was down-regulated significantly in 64.8 % (35 of 54) of cancer tissues (Fig. [1a and b](#Fig1){ref-type="fig"}, \*\*\**P* \< 0.001). Moreover, down-regulated BANCR expression was significantly correlated with advanced TNM stage (Fig. [1c](#Fig1){ref-type="fig"}, \*\**P* \< 0.01). Compared with the SV-HUC-1 cell line, the BANCR expression was decreased significantly in bladder cancer cellsT24 and SW780 (Fig. [1d](#Fig1){ref-type="fig"}, \*\**P* \< 0.01). These data demonstrated that BANCR may function as a tumor suppressor gene in bladder cancer. Patients' clinical parameters are listed in Table [1](#Tab1){ref-type="table"}.Fig. 1The long noncoding RNA BANCR was down-regulated in bladder cancer. The relative expression levels of BANCR were determined using RT- qPCR. **a** BANCR expression levels were lower in bladder cancer tissues. **b** The relative expression level of BANCR was significantly lower in bladder cancer tissues compared with pair-matched adjacent normal bladder tissues. **c** BANCR expression levels were dramatically lower in patients with higher TNM stage. **d** BANCR expression levels were lower in bladder cancer T24 and SW780 cells than those in SV-40-immortalized human uroepithelial cells. **e** The pCDNA-BANCR significantly up-regulated the expression level of BANCR in SW780 and T24 cells. Data (**b** and **c**) are shown as mean ± SEM. Data (**d** and **e**) are shown as mean ± SD. (\*\**P* \< 0.01, \*\*\**P* \< 0.001)Table 1Correlation between BANCR expression and clinicopathological characteristics of bladder cancer patientsParametersGroupTotalBANCR expressionP valueHighLowGenderMale3816220.09Female16313Age(years)\<652912170.230≥6525718Tumor size (cm)\<32411130.065≥330822Histological gradeL209110.194H341024TNM stage0/ I151050.004\*II/III/IV39930Lymph nodes metastasisN05018320.559N1 or above413\**P* \< 0.05 was considered significant (Chi-square test between 2 groups)

Specific plasmid vectors up-regulated the expression of BANCR {#Sec14}
-------------------------------------------------------------

Bladder cancer cell lines T24 and SW780 were cultured and transfected with pCDNA-BANCR or negative control. At 48 h after transfection, the related expression level of BANCR was analyzed by qRT-PCR and the results showed that the relative expression level of BANCR in T24 and SW780 (Fig. [1e](#Fig1){ref-type="fig"}, \*\**P* \< 0.01) cells was significantly up-regulated.

Overexpression of BANCR inhibited cell proliferation {#Sec15}
----------------------------------------------------

To explore the possible impact of BANCR on the growth of bladder cancer cells, the cell proliferation activities of T24 and SW780 were determined by both CCK-8 assay and Edu assay. Compared with the negative control group, cell growth arrest was observed in bladder cancer cells T24 (Fig. [2a](#Fig2){ref-type="fig"}, [c](#Fig2){ref-type="fig"} and [e](#Fig2){ref-type="fig"}) and SW780 (Fig. [2b](#Fig2){ref-type="fig"}, [d](#Fig2){ref-type="fig"} and [f](#Fig2){ref-type="fig"}) which were cultured and transfected with pCDNA-BANCR. The results suggested that BANCR inhibits cell proliferation in bladder cancer cells.Fig. 2Overexpression of lncRNA BANCR inhibited cell proliferation in bladder cancer cells. Cell proliferation was detected by both CCK-8 assay and Edu assay. Cell proliferation inhibition was observed in bladder cancer T24 (**a**, **c** and **e**), SW780 (**b**, **d** and **f**). Data are shown as mean ± SD. (\*\**P* \< 0.01, \*\*\**P* \< 0.001)

Overexpression of BANCR induced apoptosis {#Sec16}
-----------------------------------------

Furthermore, we investigated whether BANCR could induce cell apoptosis in bladder cancer. Bladder cancerT24 and SW780 cells were transfected with pCDNA-BANCR or negative control. The relative activity of caspase-3 was determined using the caspase 3 enzyme-linked immunosorbent assay (ELISA) (Fig. [3a, d](#Fig3){ref-type="fig"}) and the apoptosis ratio in bladder cancer cells was measured using flow cytometry assay. (Figure [3b, c, e and f](#Fig3){ref-type="fig"}). Induced cell apoptosis was observed in both bladder cancer and SW780 cell lines. These results indicated that BANCR induces cell apoptosis in bladder cancer.Fig. 3Overexpression of lncRNA BANCR induced cell apoptosis in bladder cancer cells. Cell apoptosis was determined by both ELISA assay and Flow cytometry. Induced cell apoptosis was observed in bladder cancer T24 (**a**, **b** and **c**) and SE780 (**d**, **e** and **f**) cells. Data are shown as mean ± SD. (\*\**P* \< 0.01, \*\*\**P* \< 0.001)

Overexpression of BANCR inhibited cell migration {#Sec17}
------------------------------------------------

Lastly, we further determined whether BANCR suppressed cell migration in bladder cancer. The cell migration activities of bladder cancer T24 and SW780 cells transfected with pCDNA-BANCR or negative control were determined by transwell assay. Cell migration arrest was observed in T24 (Fig. [4a, b](#Fig4){ref-type="fig"}), SW780 (Fig. [4c, d](#Fig4){ref-type="fig"}) as expected. These results manifested that BANCR inhibits cell migration in bladder cancer.Fig. 4overexpression of lncRNA BANCR inhibited cell migration in bladder cancer cells. Cell migration was detected by transwell assay. Cell migration inhibition was observed in bladder cancer T24 (**a** and **b**) and SW780 (**c** and **d**) cells. Data are shown as mean ± SD. (\*\**P* \< 0.01, \*\*\**P* \< 0.001)

Discussion {#Sec18}
==========

Until now, lots of works indicate that lncRNAs play vital regulatory roles in tumorigenesis and tumor progression and act as potential oncogenes or tumor suppressor genes \[[@CR19], [@CR20]\]. Recently, several lncRNAs have been found to play an emerging role in various cancers, contributing to tumor proliferation, apoptosis, and survival, such as PANDAR \[[@CR18]\], MEG3 \[[@CR21]\].

BANCR, firstly found by Flockhart RJ et al. \[[@CR22]\], has been discovered to be up-regulated in some kinds of tumors, including retinoblastoma, melanoma, papillary thyroid carcinoma, gastric cancer and hepatocellular carcinoma. In contrast, decreased expression of BANCR has been found in both colorectal and lung cancers. BANCR promotes cell proliferation by regulating MAPK pathway activation in both malignant melanoma and lung carcinoma \[[@CR14], [@CR23]\]. Besides, downregulation of BANCR promotes colorectal cancer cell proliferation through decreasing expression of p21 protein \[[@CR10]\]. Furthermore, BANCR expression promoted non-small cell lung cancer cell migration and invasion through regulating E-cadherin, N-cadherin and Vimentin expression, all of which play crucial roles in epithelial-mesenchymal transition (EMT) \[[@CR24]\]. These evidences suggest that BANCR may be involved in different signaling pathways and plays its unique role in each cancer. However, the functions of BANCR in bladder cancer were completely unknown.

To the best of our knowledge, this is the first evidence that BANCR was significantly downregulated in bladder cancer tissues compared with adjacent noncancerous tissues, and low BANCR expression in bladder cancer patients was positively correlated with advanced TNM stage. Furthermore, compared with the SV-HUC-1 cell line, the BANCR expression in bladder cancer cell lines (T24, SW780) was also obviously downregulated. These results manifest that lncRNA BANCR may emerge as a novel player in bladder cancer. To further explore the biological functions of lncRNA BANCR, we detected the cell proliferation, apoptosis and migration by overexpressing BANCR in bladder cancer T24 and SW780 cells. pCDNA-BANCR-mediated overexpression of BANCR significantly inhibited proliferation, promoted apoptosis and suppressed metastasis capabilities of bladder cancer T24 and SW780 cells compared with control group, suggesting that up-regulated BANCR expression could suppress the progression and development of bladder cancer.

Conclusion {#Sec19}
==========

In conclusion, the present study suggested that lncRNA BANCR was decreased in BC tissues and correlated with advanced TNM stage. Moreover, we preliminarily revealed the significant function of BANCR in regulating cell proliferation, apoptosis, and migration of BC cells. These findings indicated that BANCR may emerge as a tumor suppressor gene and could become a novel promising candidate for the prognosis and therapy for BC in the future. However, the prognostic role of BANCR should be verified in a larger case series, composed by firstly diagnosed patients, treated with TURB instead of cystectomy and with a minimum of 3 years of follow up. Moreover, the molecular mechanism by which BANCR was decreased in bladder cancer also should be investigated in the future works.
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